Visual Science and Optometry Center, the People's Hospital of Guangxi Zhuang Autonomous Region, Nanning, 530021, Guangxi Zhuang Autonomous Region, China.
Department of Ophthalmology, NHC Key Laboratory of Myopia, Shanghai Research Center of Ophthalmology and Optometry, Eye and ENT Hospital of Fudan University, 200433, Shanghai, China.
BMC Ophthalmol. 2023 Jul 31;23(1):341. doi: 10.1186/s12886-023-03050-9.
To compare the 4-year visual outcomes of implantable collamer lens V4c (EVO-ICL) implantation and small incision lenticule extraction (SMILE) for high myopia and astigmatism.
This retrospective case study included 64 eyes of 40 patients. These patients with preoperative manifest refraction spherical equivalent (SE) between - 6.00 and - 10.00 diopters (D) were screened from the database of SMILE and EVO-ICL implantation procedures in 2015. The ICL group [32 eyes of 19 patients (mean age, 29.6 ± 6.3 years); mean SE, -8.71 ± 1.06 D] and SMILE group [32 eyes of 21 patients (mean age, 27.7 ± 5.6 years); mean SE, -8.35 ± 0.65D] were compared. All patients were then prospectively examined at a four-year follow-up for routine postoperative examinations, higher-order ocular aberrations, retinal image quality and a questionnaire.
The safety indexes were 1.15 ± 0.14 and 1.22 ± 0.21 (P = 0.36) for the SMILE and ICL groups, respectively. No eyes lost two or more lines of CDVA in either group. The efficacy indexes were 0.97 ± 0.16 and 0.96 ± 0.19 (P = 0.87), respectively. Twenty-three eyes (72%) in ICL and 26 eyes (81%) in SMILE groups were within ± 0.5 D of the attempted SE (P < 0.01). ICL-treated eyes had significantly less spherical aberration and coma (P < 0.01 and < 0.05, respectively) postoperatively. Halos were the prevalent visual disturbance in both groups.
SMILE and EVO-ICL implantation provided safe and effective correction of high myopia. SMILE showed slightly better long-term predictability. Mild postoperative visual disturbances were observed after ICL and SMILE at 4-year follow-up.
比较可植入 Collamer 透镜 V4c(EVO-ICL)植入术和小切口微透镜提取术(SMILE)治疗高度近视和散光的 4 年视觉效果。
本回顾性病例研究纳入了 2015 年 SMILE 和 EVO-ICL 植入手术数据库中筛选出的 40 例患者的 64 只眼。这些患者术前的明视屈光球镜等效值(SE)在-6.00 至-10.00 屈光度(D)之间。ICL 组[32 只眼,19 例患者(平均年龄,29.6±6.3 岁);平均 SE,-8.71±1.06D]和 SMILE 组[32 只眼,21 例患者(平均年龄,27.7±5.6 岁);平均 SE,-8.35±0.65D]进行了比较。所有患者在 4 年的随访中均接受了常规术后检查、高阶眼像差、视网膜图像质量和问卷调查。
SMILE 组和 ICL 组的安全性指标分别为 1.15±0.14 和 1.22±0.21(P=0.36)。两组均无患者视力丧失两行或更多行。疗效指标分别为 0.97±0.16 和 0.96±0.19(P=0.87)。ICL 组 23 只眼(72%)和 SMILE 组 26 只眼(81%)术后均在目标 SE±0.5 D 范围内(P<0.01)。ICL 治疗眼术后球差和彗差明显减少(P<0.01 和<0.05)。两组术后均以光晕为主要视觉干扰。
SMILE 和 EVO-ICL 植入术为高度近视提供了安全有效的矫正。SMILE 显示出稍好的长期预测性。在 4 年随访时,ICL 和 SMILE 术后均观察到轻度的术后视觉干扰。